# Alzheimer s Research & Therapy

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/alzheimer-s-research-and-therapy/

## Facts

| Field | Value |
| --- | --- |
| Open Access | true |
| ISSN-L | 1758-9193 |
| ISSNs | 1758-9193 |
| OpenAlex ID | https://openalex.org/S140755874 |
| Publisher | BioMed Central |

## Journal papers

Showing 12 of 29.

- [Recent global trends in the prevalence and incidence of dementia, and survival with dementia](https://scholariq.org/papers/recent-global-trends-in-the-prevalence-and-incidence-of-dementia-and-survival/)
- [Alzheimer’s disease prevention: from risk factors to early intervention](https://scholariq.org/papers/alzheimer-s-disease-prevention-from-risk-factors-to-early-intervention/)
- [On the path to 2025: understanding the Alzheimer’s disease continuum](https://scholariq.org/papers/on-the-path-to-2025-understanding-the-alzheimer-s-disease-continuum/)
- [Drug development in Alzheimer’s disease: the path to 2025](https://scholariq.org/papers/drug-development-in-alzheimer-s-disease-the-path-to-2025/)
- [Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)](https://scholariq.org/papers/design-and-first-baseline-data-of-the-dzne-multicenter-observational-study-on/)
- [Clinical prevalence of Lewy body dementia](https://scholariq.org/papers/clinical-prevalence-of-lewy-body-dementia/)
- [A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia](https://scholariq.org/papers/a-36-week-multicenter-randomized-double-blind-placebo-controlled-parallel-group/)
- [Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease](https://scholariq.org/papers/comparison-of-amyloid-pet-measured-in-centiloid-units-with-neuropathological/)
- [Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study](https://scholariq.org/papers/estimating-prevalence-of-subjective-cognitive-decline-in-and-across/)
- [FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study](https://scholariq.org/papers/fdg-pet-as-an-independent-biomarker-for-alzheimer-s-biological-diagnosis-a/)
- [Depression, subjective cognitive decline, and the risk of neurocognitive disorders](https://scholariq.org/papers/depression-subjective-cognitive-decline-and-the-risk-of-neurocognitive-disorders/)
- [Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study](https://scholariq.org/papers/which-features-of-subjective-cognitive-decline-are-related-to-amyloid-pathology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.